Arcus Biosciences, Inc.
RCUSNYSE
$27.37
↑ +2.7%Jul 17 close · end-of-day
Price
1Y↑ +195.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$3.4B
Enterprise Value
$2.7B
P/E
—
P/S
14.5
P/B
6.5
EV/EBITDA
—
PEG
—
FCF Yield
-14.2%
Dividend Yield
—
Revenue (TTM)
$236.0M
Net Income (TTM)
-$369.0M
Free Cash Flow (TTM)
-$489.0M
Gross Margin
—
Operating Margin
-168.6%
Net Margin
-156.4%
ROE
-70.4%
ROIC
—
Debt / Equity
0.2
Net Cash
$722.0M
Return 1Y
+190.6%
Company profile
Arcus Biosciences, Inc. develops and commercializes cancer therapies in the United States. Its product pipeline includes Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company was incorporated in 2015 and is headquartered in Hayward, California.
- CEO
- Terry J. Rosen
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 500
- Headquarters
- California
- Website
- arcusbio.com
Management & directors
- Jaen Juan C.President
- Tang Carolyn C.General Counsel
- Azoy AlexanderChief Accounting Officer
- Goeltz Ii Robert C.Chief Financial Officer
- Jarrett JenniferChief Operating Officer
- Markus RichardChief Medical Officer
- Rosen Terry JChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
RCUS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$17.0M↓ -39.3%
Diluted EPS-$1.02↓ -10.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $78.0M | $383.0M | $112.0M | $117.0M | $258.0M | $247.0M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$124.0M | $54.0M | -$280.0M | -$340.0M | -$330.0M | -$386.0M |
| Net income | -$123.0M | $53.0M | -$267.0M | -$307.0M | -$283.0M | -$353.0M |
| Diluted EPS | -$2.24 | $0.71 | -$3.71 | -$4.15 | -$3.14 | -$3.29 |
| Operating cash flow | $111.0M | -$256.0M | $438.0M | -$306.0M | -$170.0M | -$482.0M |
| Free cash flow | $108.0M | -$282.0M | $432.0M | -$330.0M | -$176.0M | -$484.0M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -159.0% | 14.1% | -250.0% | -290.6% | -127.9% | -156.3% |
| Net margin | -157.7% | 13.8% | -238.4% | -262.4% | -109.7% | -142.9% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $39.0M | $48.0M | $26.0M | $28.0M | $160.0M | $26.0M | $33.0M | $17.0M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$106.0M | -$105.0M | -$103.0M | -$122.0M | -$8.0M | -$142.0M | -$114.0M | -$134.0M |
| Net income | -$93.0M | -$92.0M | -$94.0M | -$112.0M | $0.00 | -$135.0M | -$106.0M | -$128.0M |
| Diluted EPS | -$1.02 | -$1.00 | -$1.07 | -$1.14 | $0.00 | -$1.27 | -$0.88 | -$1.02 |
| Operating cash flow | -$94.0M | $26.0M | -$100.0M | -$132.0M | -$133.0M | -$97.0M | -$120.0M | -$138.0M |
| Free cash flow | -$94.0M | $25.0M | -$101.0M | -$133.0M | -$133.0M | -$97.0M | -$121.0M | -$138.0M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -271.8% | -218.8% | -396.2% | -435.7% | -5.0% | -546.2% | -345.5% | -788.2% |
| Net margin | -238.5% | -191.7% | -361.5% | -400.0% | 0.0% | -519.2% | -321.2% | -752.9% |
Company news
Jul 1, 2026
Jun 12, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-10 | Jaen Juan C.· President | Sale | 19,799 | $28.61 | $566,409.79 | filing |
| 2026-07-10 | Jaen Juan C.· President | Sale | 268 | $29.40 | $7,878.40 | filing |
| 2026-07-09 | Jaen Juan C.· President | Sale | 48,502 | $30.05 | $1.5M | filing |
| 2026-06-24 | Jaen Juan C.· President | Sale | 6,431 | $29.66 | $190,740.24 | filing |
| 2026-06-23 | Jaen Juan C.· President | Sale | 14,067 | $27.69 | $389,480.06 | filing |
| 2026-06-23 | Jaen Juan C.· President | Sale | 1,697 | $28.06 | $47,619.86 | filing |
| 2026-06-22 | Jaen Juan C.· President | Sale | 9,236 | $27.03 | $249,661.09 | filing |
| 2026-06-11 | Tang Carolyn C.· General Counsel | Option exercise | 34,090 | $2.57 | $87,747.66 | filing |
| 2026-06-11 | PERLMAN ANDREW J | Award | 5,700 | $0.00 | $0.00 | filing |
| 2026-06-11 | Lambert Nicole | Award | 5,700 | $0.00 | $0.00 | filing |
| 2026-06-11 | Machado Patrick | Award | 5,700 | $0.00 | $0.00 | filing |
| 2026-06-11 | KANEKO YASUNORI | Award | 5,700 | $0.00 | $0.00 | filing |
| 2026-06-11 | Lacey David L. | Award | 5,700 | $0.00 | $0.00 | filing |
| 2026-06-11 | FALBERG KATHRYN E | Award | 5,700 | $0.00 | $0.00 | filing |
| 2026-06-11 | Ribas Antoni | Award | 5,700 | $0.00 | $0.00 | filing |
| 2026-06-01 | Azoy Alexander· Chief Accounting Officer | Sale | 2,562 | $25.77 | $66,023.76 | filing |
| 2026-05-11 | Goeltz II Robert C.· Chief Financial Officer | Sale | 7,763 | $25.63 | $198,965.69 | filing |
| 2026-01-23 | Markus Richard· Chief Medical Officer | Award | 24,000 | $0.00 | $0.00 | filing |
| 2026-01-23 | ROSEN TERRY J· Chief Executive Officer | Award | 79,000 | $0.00 | $0.00 | filing |
| 2026-01-23 | Jaen Juan C.· President | Award | 31,000 | $0.00 | $0.00 | filing |
| 2026-01-23 | Tang Carolyn C.· General Counsel | Award | 24,000 | $0.00 | $0.00 | filing |
| 2026-01-23 | Goeltz II Robert C.· Chief Financial Officer | Award | 24,000 | $0.00 | $0.00 | filing |
| 2026-01-23 | Azoy Alexander· Chief Accounting Officer | Award | 21,050 | $0.00 | $0.00 | filing |
| 2026-01-23 | Jarrett Jennifer· Chief Operating Officer | Award | 31,000 | $0.00 | $0.00 | filing |
| 2026-01-08 | ROSEN TERRY J· Chief Executive Officer | Gift | 35,000 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.